PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)- Economic Modeling (EM) results
Nov 1, 2011, 00:00
10.1016/j.jval.2011.08.1168
https://www.valueinhealthjournal.com/article/S1098-3015(11)02730-6/fulltext
Title :
PCN67 Erlotinib as Second Line Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC)- Economic Modeling (EM) results
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)02730-6&doi=10.1016/j.jval.2011.08.1168
First page :
A446
Section Title :
Cancer
Open access? :
No
Section Order :
1125